Gilead Sciences Articles
Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program
3 May 2013
Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting
24 April 2013
Regulatory briefs: Gilead files sofosbuvir; FDA approves Diclegis; Health Canada clears Dysport
9 April 2013
Actavis confirms generic Exelon Patch patent challenge; InnoPharma debuts generic Vistide in USA
9 March 2013
Gilead and Teva settle Viread patent litigation
20 February 2013
Patient trust in drugmakers declining, new report shows
14 January 2013
Gilead Sciences updates on hepatitis C development programs
7 January 2013
Gilead agrees to buy YM BioSciences for $510 million
13 December 2012
Japan Tobacco files for Japanese approval of elvitegravir
11 December 2012
EU approvals for Viread and Constella; EMA accepts vintafolide MAA
29 November 2012
New Zealand to fund Gilead's Atripla and Truvada
27 November 2012
Gilead HIV drugs Atripla and Truvada to be listed in New Zealand
13 November 2012
Clinical briefs from Novartis, Gilead and AstraZeneca
13 November 2012
Gilead's Stribild, formerly "Quad," gets FDA nod
29 August 2012
Gilead abandons development of PAH drug cicletanine
23 August 2012
FDA approves Truvada, first drug for reducing the risk of sexually acquired HIV infection
17 July 2012
New briefs: GSK extends HGS tender offer; J&J plans for $600 million charge; FDA delays prophylactic Truvada
10 June 2012
News briefs: Genmab/GSK, Gilead and Mylan
24 May 2012
Germany's G-BA backs Eisai's Halaven; IQWiG finds some added benefit for Eliquis and rilpivirine
23 April 2012
Adimab enters new antibody discovery programs
19 April 2012
Setback for Gilead’s oral hep C drug candidate
20 February 2012
US FDA priority review for Truvada for reducing HIV risk
15 February 2012
2011 financial briefs for Alkermes, Allergan, Gilead and Vertex
3 February 2012
FDA backs Gilead’s Viread for children
20 January 2012
Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad
28 December 2011
Gilead filing of Truvada for PrEP looks contentious
19 December 2011
More cancer and HIV drugs added to Australian PBS
7 December 2011
Gilead and Johnson & Johnson get EU backing for HIV drugs Eviplera and Edurant, respectively
29 November 2011
Gilead’s Quad regimen to be HIV market leader in 2020, with over $3 billion sales, says Decision Resources
31 October 2011
Gilead collaborates with GlobeImmune to develop vaccine for chronic hepatitis B infection
25 October 2011
More news from EMA/CHMP September meeting
26 September 2011
Gilead’s investigational Quad HIV regimen meets primary endpoint in Pivotal Ph III study
16 August 2011
Gilead gains US approval for Complera, resolves manufacturing problem and buys Genentech facility
11 August 2011
Ranbaxy and Mylan unit to make and market three Gilead HIV drugs in developing countries
13 July 2011
AHF lambasts Gilead over HIV drug price hikes
6 April 2011
Gilead to acquire Calistoga in $375 million, plus milestones, deal
23 February 2011
US FDA grants pediatric exclusivity for Sanofi/B-MS Plavix; rejects Gilead’s filing for combination AIDS pill
26 January 2011
Gilead Sciences gets rights to IPF and lung cancer drug with $225 million acquisition of Arresto Biosciences
21 December 2010
Breakthrough research shows Gilead antiretroviral Truvada can prevent HIV in men who have sex with men
24 November 2010
Liver disease meeting hears updates on Merck & Co’s boceprevir, Boehringer Ingelheim’s HCV combo, Vertex’ telaprevir and Gilead’s Viread
2 November 2010
Gilead files patent infringement suit against Lupin over Ranexa; Mylan’s generic nabumetone cleared by FDA
16 July 2010
Batch of positive opinions from Europe's Committee for Medicinal Products for Human Use recent meetings
28 June 2010
Biotech - the battle of branded drugs and generics
28 June 2010
Gilead Sciences to freeze and lower HIV drug prices to support AIDS Drug Assistance Programs
7 June 2010
Three novel HIV products from Gilead and Tibotec will earn combined peak year sales of over $5 billion
3 June 2010
J&J posts higher first-quarter 2010 profit, boosted by one-time gain, but lowers forecast; updates on Truvada combo n HIV
21 April 2010
US FDA approves Boehringer Ingelheim’s once-daily Mirapex ER for early Parkinson's disease and Gilead’s Cayston for cystic fibrosis
23 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
